A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
← catalyst calendarNCT05827016 · readout in 938 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,230actual
Sites
271
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-22 | actual | When the study began enrolling |
| Primary completion | 2029-03-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-01-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Iberdomide — also filed as CC-220, BMS-986382
- Drug: Lenalidomide — also filed as Revlimid®
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Up to 6 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed